Entero Therapeutics Welcomes Richard Paolone as CEO
Entero Therapeutics, Inc. (NASDAQ: ENTO), a dynamic biopharmaceutical entity at the forefront of developing specialized therapies for gastrointestinal (GI) conditions, announced the recent appointment of Richard Paolone as their interim CEO.
Introducing Richard Paolone
Mr. Richard Paolone, based in Toronto, is not just a securities lawyer; he brings a wealth of experience in corporate finance, securities law, and mergers and acquisitions. Over the years, Paolone has shaped the landscape of advice given to various companies regarding strategic business initiatives and has represented a myriad of businesses during private and public offerings involving equity and debt securities. His thorough understanding of capital markets and regulatory dynamics has been pivotal in facilitating numerous successful mergers and acquisitions, alongside initial public offerings.
Supporting Business Growth
Relying on his transactional expertise, Paolone has solidified his reputation as a trusted advisor for management teams and corporate boards. His commitment to ensuring legal compliance while promoting organizational growth underlines his role as a vital asset to the company. His extensive experience includes serving as a director or officer in several firms, both public and private, where he has shared insights and strategic advice tailored to guiding these entities in their highly competitive respective markets.
About Entero Therapeutics
Entero Therapeutics is a late clinical-stage biopharmaceutical firm wholly focused on developing targeted therapies that operate non-systemically to tackle pressing GI disorders. Their innovative programs address significant unmet medical needs in the field of GI health. This includes pioneering projects such as latiglutenase, which is poised to become a first-in-class, oral biotherapeutic addressing celiac disease; capeserod, targeting the selective 5-HT4 receptor and showing promise for conditions including gastroparesis; and adrulipase, a unique recombinant lipase enzyme that assists with fat digestion and nutrient absorption specific to patients with cystic fibrosis and chronic pancreatitis experiencing exocrine pancreatic insufficiency.
Company Contact Information
For further inquiries, you can reach Entero Therapeutics, Inc. at:
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
Email: info@enterothera.com
Investor Relations Contact
For any investor-related enquiries:
Entero Investor Relations
Email: investors@enterothera.com
Frequently Asked Questions
Who is the new CEO of Entero Therapeutics?
The new CEO of Entero Therapeutics is Richard Paolone, who has a substantial background in corporate law and finance.
What experience does Richard Paolone bring to Entero?
Richard Paolone has extensive experience in corporate finance, securities law, and mergers and acquisitions, making him a valuable asset for Entero Therapeutics.
What is the focus of Entero Therapeutics?
Entero Therapeutics focuses on developing targeted, non-systemic therapies for gastrointestinal diseases, addressing significant unmet medical needs.
What are some of Entero's key programs?
Some key programs include latiglutenase for celiac disease, capeserod for gastroparesis, and adrulipase for patients with cystic fibrosis and chronic pancreatitis.
How can I contact Entero Therapeutics?
You can contact Entero Therapeutics through their main office at 777 Yamato Road, Boca Raton, or via email at info@enterothera.com.
